ଭିବେଗ୍ରନ

ଭିବେଗ୍ରନ
Clinical data
Trade names	Gemtesa
Synonyms	RVT-901; MK4618; KRP114V; URO-901
AHFS/Drugs.com	monograph
data	US DailyMed: Vibegron;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	49.6 to 51.3% is bound to plasma proteins
Metabolism	Predominantly oxidation and glucuronidation
Elimination half-life	60 to 70 hours
Excretion	59% feces (54% of this is in the unchanged parent drug form), 20% urine (19% of this is in the unchanged parent drug form)
Identifiers
	IUPAC name (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide;
ECHA InfoCard	100.210.547
Chemical and physical data
Formula	C26H28N4O3
Molar mass	୪୪୪.୫୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21;
	InChI InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1; Key:DJXRIQMCROIRCZ-XOEOCAAJSA-N;

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Vibegron

ଭିବେଗ୍ରନ (ଇଂରାଜୀ ଭାଷାରେ Vibegron), ଜେମେଟା ତାହାର ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅତିସକ୍ରିୟ ମୂତ୍ରାଶୟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ^[୪] ଏହା ଅନିଚ୍ଛାକୃତ ମୂତ୍ରତ୍ୟାଗ, ଜରୁରୀତା ଏବଂ ପୁନଃପୌନିକ ମୂତ୍ର ତ୍ୟାଗ ଲକ୍ଷଣରେ ଉନ୍ନତି ଆଣିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ମୂତ୍ରନଳୀ ସଂକ୍ରମଣ, ତରଳ ଝାଡ଼ା, ଅଇ ଏବଂ ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ ହୋଇପାରେ ।^[୧] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୂତ୍ର ଧାରଣ (urinary retention) ହୋଇପାରେ । ^[୧] ଗୁରୁତର ବୃକ୍‌କ କିମ୍ବା ଯକୃତ ସମସ୍ୟା ଥିବା ଲୋକଙ୍କଠାରେ ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୧] ଏହା ଏକ ନିର୍ବାଚିତ (ସିଲେକ୍ଟିଭ୍) ବିଟା<sub id="mwKA">୩</sub> ଆଡ୍ରେନର୍ଜିକ୍ ରିସେପ୍ଟର ଆଗୋନିଷ୍ଟ ।^[୫]

୨୦୧୮ ମସିହାରେ ଜାପାନରେ ଏବଂ ୨୦୨୦ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଭିବେଗ୍ରନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୬] ୨୦୨୨ ସୁଦ୍ଧା ବ୍ରିଟେନ କିମ୍ବା ୟୁରୋପରେ ଏହା ଅନୁମୋଦିତ ହୋଇନଥିଲା ।^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ସୁଦ୍ଧା ମାସକୁ ଏହା ପିଛା ପ୍ରାୟ ୪୬୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ ^୧.୮ "Gemtesa- vibegron tablet, film coated". DailyMed. Archived from the original on 14 January 2021. Retrieved 12 January 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ Rechberger T, Wróbel A (January 2021). "Evaluating vibegron for the treatment of overactive bladder". Expert Opinion on Pharmacotherapy. 22 (1): 9–17. doi:10.1080/14656566.2020.1809652. ISSN 1465-6566. PMID 32993398. S2CID 222166213. Archived from the original on 2021-07-17. Retrieved 2022-09-15.
↑ Urovant Sciences GmbH (2020). "HIGHLIGHTS OF PRESCRIBING INFORMATION GEMTESA" (PDF). Archived (PDF) from the original on 2021-07-17. Retrieved 2022-09-15.
↑ "Drug Trials Snapshot: Gemtesa". U.S. Food and Drug Administration (FDA). 23 December 2020. Archived from the original on 12 January 2021. Retrieved 12 January 2021.
↑ "Vibegron Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 1 November 2022.
↑ ^୬.୦ ^୬.୧ "Vibegron". SPS - Specialist Pharmacy Service. 25 January 2016. Archived from the original on 4 December 2021. Retrieved 1 November 2022.
↑ "Gemtesa". Archived from the original on 1 November 2022. Retrieved 1 November 2022.

[PI2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ ^୧.୮ "Gemtesa- vibegron tablet, film coated". DailyMed. Archived from the original on 14 January 2021. Retrieved 12 January 2021.

[:4-2] ୨.୦ ^୨.୧ ^୨.୨ Rechberger T, Wróbel A (January 2021). "Evaluating vibegron for the treatment of overactive bladder". Expert Opinion on Pharmacotherapy. 22 (1): 9–17. doi:10.1080/14656566.2020.1809652. ISSN 1465-6566. PMID 32993398. S2CID 222166213. Archived from the original on 2021-07-17. Retrieved 2022-09-15.

[:6-3] Urovant Sciences GmbH (2020). "HIGHLIGHTS OF PRESCRIBING INFORMATION GEMTESA" (PDF). Archived (PDF) from the original on 2021-07-17. Retrieved 2022-09-15.

[Snap2022-4] "Drug Trials Snapshot: Gemtesa". U.S. Food and Drug Administration (FDA). 23 December 2020. Archived from the original on 12 January 2021. Retrieved 12 January 2021.

[AHFS2022-5] "Vibegron Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 1 November 2022.

[SPS2022-6] ୬.୦ ^୬.୧ "Vibegron". SPS - Specialist Pharmacy Service. 25 January 2016. Archived from the original on 4 December 2021. Retrieved 1 November 2022.

[7] "Gemtesa". Archived from the original on 1 November 2022. Retrieved 1 November 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]